Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial methionyl-tRNA formyltransferase (MTFMT) is an enzyme encoded by the nuclear MTFMT gene that localizes to mitochondria, where it catalyzes the formylation of methionyl-tRNA (Met-tRNA), a key step required for translation initiation in mitochondria[2][4][5]. This activity parallels the initiation seen in bacteria, as mammalian mitochondria use N-formylmethionine to start protein synthesis. Mutations in MTFMT significantly reduce mitochondrial translation efficiency and are associated with mitochondrial diseases such as Leigh syndrome and combined oxidative phosphorylation deficiency, due to defective synthesis of mitochondrial proteins necessary for respiratory chain function[1][2][6].
Inhibition or modulation of MTFMT could affect mitochondrial translation and energy metabolism (inference based on function)[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial methionyl-tRNA formyltransferase (MTFMT).